Cargando…

A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle

BACKGROUND: Aggressive lipid lowering with high doses of statins increases the risk of statin-induced myopathy. However, the cellular mechanisms leading to muscle damage are not known and sensitive biomarkers are needed to identify patients at risk of developing statin-induced serious side effects....

Descripción completa

Detalles Bibliográficos
Autores principales: Laaksonen, Reijo, Katajamaa, Mikko, Päivä, Hannu, Sysi-Aho, Marko, Saarinen, Lilli, Junni, Päivi, Lütjohann, Dieter, Smet, Joél, Van Coster, Rudy, Seppänen-Laakso, Tuulikki, Lehtimäki, Terho, Soini, Juhani, Orešič, Matej
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762369/
https://www.ncbi.nlm.nih.gov/pubmed/17183729
http://dx.doi.org/10.1371/journal.pone.0000097
_version_ 1782131552878067712
author Laaksonen, Reijo
Katajamaa, Mikko
Päivä, Hannu
Sysi-Aho, Marko
Saarinen, Lilli
Junni, Päivi
Lütjohann, Dieter
Smet, Joél
Van Coster, Rudy
Seppänen-Laakso, Tuulikki
Lehtimäki, Terho
Soini, Juhani
Orešič, Matej
author_facet Laaksonen, Reijo
Katajamaa, Mikko
Päivä, Hannu
Sysi-Aho, Marko
Saarinen, Lilli
Junni, Päivi
Lütjohann, Dieter
Smet, Joél
Van Coster, Rudy
Seppänen-Laakso, Tuulikki
Lehtimäki, Terho
Soini, Juhani
Orešič, Matej
author_sort Laaksonen, Reijo
collection PubMed
description BACKGROUND: Aggressive lipid lowering with high doses of statins increases the risk of statin-induced myopathy. However, the cellular mechanisms leading to muscle damage are not known and sensitive biomarkers are needed to identify patients at risk of developing statin-induced serious side effects. METHODOLOGY: We performed bioinformatics analysis of whole genome expression profiling of muscle specimens and UPLC/MS based lipidomics analyses of plasma samples obtained in an earlier randomized trial from patients either on high dose simvastatin (80 mg), atorvastatin (40 mg), or placebo. PRINCIPAL FINDINGS: High dose simvastatin treatment resulted in 111 differentially expressed genes (1.5-fold change and p-value<0.05), while expression of only one and five genes was altered in the placebo and atorvastatin groups, respectively. The Gene Set Enrichment Analysis identified several affected pathways (23 gene lists with False Discovery Rate q-value<0.1) in muscle following high dose simvastatin, including eicosanoid synthesis and Phospholipase C pathways. Using lipidomic analysis we identified previously uncharacterized drug-specific changes in the plasma lipid profile despite similar statin-induced changes in plasma LDL-cholesterol. We also found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. CONCLUSIONS: High dose simvastatin affects multiple metabolic and signaling pathways in skeletal muscle, including the pro-inflammatory pathways. Thus, our results demonstrate that clinically used high statin dosages may lead to unexpected metabolic effects in non-hepatic tissues. The lipidomic profiles may serve as highly sensitive biomarkers of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity.
format Text
id pubmed-1762369
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-17623692007-01-04 A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle Laaksonen, Reijo Katajamaa, Mikko Päivä, Hannu Sysi-Aho, Marko Saarinen, Lilli Junni, Päivi Lütjohann, Dieter Smet, Joél Van Coster, Rudy Seppänen-Laakso, Tuulikki Lehtimäki, Terho Soini, Juhani Orešič, Matej PLoS One Research Article BACKGROUND: Aggressive lipid lowering with high doses of statins increases the risk of statin-induced myopathy. However, the cellular mechanisms leading to muscle damage are not known and sensitive biomarkers are needed to identify patients at risk of developing statin-induced serious side effects. METHODOLOGY: We performed bioinformatics analysis of whole genome expression profiling of muscle specimens and UPLC/MS based lipidomics analyses of plasma samples obtained in an earlier randomized trial from patients either on high dose simvastatin (80 mg), atorvastatin (40 mg), or placebo. PRINCIPAL FINDINGS: High dose simvastatin treatment resulted in 111 differentially expressed genes (1.5-fold change and p-value<0.05), while expression of only one and five genes was altered in the placebo and atorvastatin groups, respectively. The Gene Set Enrichment Analysis identified several affected pathways (23 gene lists with False Discovery Rate q-value<0.1) in muscle following high dose simvastatin, including eicosanoid synthesis and Phospholipase C pathways. Using lipidomic analysis we identified previously uncharacterized drug-specific changes in the plasma lipid profile despite similar statin-induced changes in plasma LDL-cholesterol. We also found that the plasma lipidomic changes following simvastatin treatment correlate with the muscle expression of the arachidonate 5-lipoxygenase-activating protein. CONCLUSIONS: High dose simvastatin affects multiple metabolic and signaling pathways in skeletal muscle, including the pro-inflammatory pathways. Thus, our results demonstrate that clinically used high statin dosages may lead to unexpected metabolic effects in non-hepatic tissues. The lipidomic profiles may serve as highly sensitive biomarkers of statin-induced metabolic alterations in muscle and may thus allow us to identify patients who should be treated with a lower dose to prevent a possible toxicity. Public Library of Science 2006-12-20 /pmc/articles/PMC1762369/ /pubmed/17183729 http://dx.doi.org/10.1371/journal.pone.0000097 Text en Laaksonen et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Laaksonen, Reijo
Katajamaa, Mikko
Päivä, Hannu
Sysi-Aho, Marko
Saarinen, Lilli
Junni, Päivi
Lütjohann, Dieter
Smet, Joél
Van Coster, Rudy
Seppänen-Laakso, Tuulikki
Lehtimäki, Terho
Soini, Juhani
Orešič, Matej
A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
title A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
title_full A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
title_fullStr A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
title_full_unstemmed A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
title_short A Systems Biology Strategy Reveals Biological Pathways and Plasma Biomarker Candidates for Potentially Toxic Statin-Induced Changes in Muscle
title_sort systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762369/
https://www.ncbi.nlm.nih.gov/pubmed/17183729
http://dx.doi.org/10.1371/journal.pone.0000097
work_keys_str_mv AT laaksonenreijo asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT katajamaamikko asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT paivahannu asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT sysiahomarko asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT saarinenlilli asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT junnipaivi asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT lutjohanndieter asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT smetjoel asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT vancosterrudy asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT seppanenlaaksotuulikki asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT lehtimakiterho asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT soinijuhani asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT oresicmatej asystemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT laaksonenreijo systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT katajamaamikko systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT paivahannu systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT sysiahomarko systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT saarinenlilli systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT junnipaivi systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT lutjohanndieter systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT smetjoel systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT vancosterrudy systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT seppanenlaaksotuulikki systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT lehtimakiterho systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT soinijuhani systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle
AT oresicmatej systemsbiologystrategyrevealsbiologicalpathwaysandplasmabiomarkercandidatesforpotentiallytoxicstatininducedchangesinmuscle